Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Drug Market for Metabolic Diseases to Grow to ¥430 Bil. in 2019: Fuji-Keizai
July 4, 2011
- MTPC Expects 8 Launches in FY2011
July 4, 2011
- Generics of Actos Listed from 18 Companies
July 4, 2011
- MTPC, JCRS to Integrate Their Plasma Fraction Products Business in April 2012
July 4, 2011
- Actos Generics Launched Despite Various Issues
July 4, 2011
- FUJIFILM, Mitsubishi Corp. Tie-up to Contract Manufacture Biopharmaceuticals
July 4, 2011
- Nihon Chouzai to Invest ¥10 Bil. to Increase GE Production Capacity
July 4, 2011
- Price Settlement Rate Up to 93.9% in March: Korosho
July 4, 2011
- FDA Approves Generics of Levofloxacin from 12 Companies
July 4, 2011
- Equa Ranked No. 1 Both in GP, HP Markets in April: RepTrack Survey
July 4, 2011
- Industry Submits Proposal to Freeze Prices of Essential Drugs
July 4, 2011
- Korosho Designates 5 Products including Dornase as Orphan Drugs
July 4, 2011
- Ethical Drug Market in Japan Grew 1.6% to ¥9,035,806 Mil. in FY2010: IMS Japan
July 4, 2011
- METI Advisory Committee Proposes Exclusion of OTC-like Drugs from Insurance Coverage
July 4, 2011
- Mediceo Aims to Attract More Customers in Nagoya Area through New ALC
June 27, 2011
- Sanofi to Apply for Zaltrap for mCRC in Europe, US in 2011
June 27, 2011
- Terumo to Expand into Infusion Products Market in China
June 27, 2011
- MSD, Taiho Announce Marketing Tie-up for CTCL Treatment Vorinostat
June 27, 2011
- More Companies Collaborating in Development of Combination Therapies Using New Drugs
June 27, 2011
- Further Analysis Confirms Usefulness of SGN-36: Takeda
June 27, 2011
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…